Infections Clinical Trials

539 recruitingLast updated: July 11, 2026

There are 539 actively recruiting infections clinical trials across 80 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include New York, New York, United States, Paris, France, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Infections Trials at a Glance

539 actively recruiting trials for infections are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Not Applicable with 157 trials, with the heaviest enrollment activity in New York, Paris, and Houston. Lead sponsors running infections studies include National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Infections Clinical Trials

Looking for clinical trials for Infections? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Infections trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Infections clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 539 trials

Recruiting
Phase 3

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

HIV Infections
Africa Health Research Institute2,052 enrolled1 locationNCT06250504
Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

PneumoniaInfectionsImmune System Diseases+2 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00006150
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting
Not Applicable

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

HIV Infections
Center for Innovative Public Health Research5,000 enrolled2 locationsNCT06230367
Recruiting
Phase 1

Dasatinib for HIV-1 Reservoir Reduction

HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)14 enrolled3 locationsNCT07342491
Recruiting
Phase 4

Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)

Bacterial InfectionsDecompensated Cirrhosis
Eva Bonfill198 enrolled1 locationNCT05783661
Recruiting
Not Applicable

Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting

Urinary Tract Infections
University Hospitals Cleveland Medical Center47 enrolled1 locationNCT06976125
Recruiting

Diagnosis and Treatment of Leishmania Infections

LeishmaniasisSkin Diseases, ParasiticEuglenozoa Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID)289 enrolled1 locationNCT00344188
Recruiting
Phase 1Phase 2

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NeutropeniaInfectionsWarts+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT00967785
Recruiting

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Staphylococcal Infections
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled2 locationsNCT06479837
Recruiting
Phase 3

Comparison of Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.

TherapyPleural Infections
Centre Hospitalier Universitaire, Amiens244 enrolled1 locationNCT07666464
Recruiting
Phase 1

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

HIV Infections
ViiV Healthcare9 enrolled1 locationNCT07636928
Recruiting
Phase 1

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections
ViiV Healthcare372 enrolled3 locationsNCT06310551
Recruiting
Not Applicable

Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

HIV Infections
Boston University266 enrolled2 locationsNCT06088277
Recruiting
Phase 2

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Gram-Negative Bacterial Infections
Pfizer48 enrolled23 locationsNCT05639647
Recruiting
Phase 3

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Respiratory Syncytial Virus Infections
Kexing Biopharm Co., Ltd.322 enrolled1 locationNCT06363370
Recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

HIV Infections
Gilead Sciences3,000 enrolled28 locationsNCT07473778
Recruiting

Novel Technologies for Respiratory Virus Identification

Respiratory Tract InfectionsInfections, Respiratory
Portsmouth Hospitals NHS Trust1,000 enrolled1 locationNCT05661032
Recruiting
Phase 4

Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up

HIV InfectionAntiretroviral TherapyLentivirus Infections
Instituto Mexicano del Seguro Social78 enrolled1 locationNCT07678268
Recruiting

Study of Mycobacterial Infections

Mycobacterium Infections
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT00018044